Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inflexal V 2010/2011 Immunogenicity and Safety Study
NCT01229371Phase 3Completed
- Sponsor
- Crucell
- Start
- Oct 2010
- Primary completion
- Dec 2010
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Inflexal V in influenza (4 arms), sponsored by Crucell. Primary endpoints: Geometric Mean Titer Fold Increase From Baseline at 3 weeks, Seroprotection Rate at 3 weeks and 1 more. Started Oct 2010; status: completed.
02
Drugs
Inflexal V
03
Conditions
influenza
Beyond the preview
Go deeper on NCT01229371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01229371.